KKR provides $600 M financing to Indian conglomerate Manipal Group

IMT News Desk
IMT News Desk
· 2 min read

Transaction marks KKR’s latest and largest credit investment in India

KKR, a leading global investment firm and Manipal Education and Medical Group, a major diversified conglomerate in India, announced a $600-million financing arranged by KKR Capital Markets and anchored by KKR’s private credit and insurance platforms to the Manipal Group. The investment will enable the Manipal Group to accelerate its corporate expansion and growth objectives by providing flexible, structured capital matched to its long-term strategic needs.
 
The Manipal Group is a leading conglomerate in India with various institutions and major businesses across the healthcare, education, and health insurance sectors, including Manipal Health Enterprises, one of India’s top multispecialty hospital chains in India.
 
KKR’s Asia Pacific Credit platform seeks to provide, among other private credit strategies, bespoke solutions to high-quality companies, entrepreneurs, promoters and sponsors that harness the strength of KKR’s private markets investment capabilities and its expertise as one of the largest alternative credit managers globally.
 
Gaurav Trehan, Co-Head of KKR Asia Pacific and Head of Asia Private Equity, KKR said, “We are pleased to deepen our relationship with the Manipal Group and Dr Ranjan Pai, who have established one of India’s pre-eminent and homegrown businesses, as they continue to deliver on their long-term vision. The Manipal Group has built a strong reputation over the decades as one of India’s healthcare and education leaders, and we look forward to supporting and contributing to their continued success.”
 
Dr Ranjan Pai, Chairman of Manipal Education and Medical Group, said, “We are proud to welcome KKR as a strategic partner as we continue to build on Manipal’s legacy in healthcare and education. KKR’s longstanding India focus and flexible capital approach, as well as alignment with our long-term vision, present a strong fit for us.”
 
Diane Raposio, Partner and Head of Asia Credit and Markets at KKR, added, “This transaction underscores the strength of our global credit platform and our ability to provide strategic, scaled capital solutions to leading businesses. India is a priority market for our credit strategy, and we look to build on this momentum to be a partner of choice to more high-quality companies like Manipal on their growth ambitions.”

Read Next

Granules India posts Rs 13,879 million revenue from operations at Q3FY26
Finance
January 28, 2026

Granules India posts Rs 13,879 million revenue from operations at Q3FY26

Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x Granules India has announced its financial results for the quarter ended December 31, 2025. Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and […]
Article by: IMT News Desk
OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26
Finance
January 28, 2026

OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26

Impacted by delayed semaglutide approvals in Canada OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. […]
Article by: IMT News Desk
Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr
Finance
January 27, 2026

Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr

Reported revenue dips to Rs 932 crore in the same quarter Syngene International announced financial results for the third quarter of FY26. Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the […]
Article by: IMT News Desk
Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427
Finance
January 27, 2026

Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427

Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks […]
Article by: IMT News Desk